Aardvark Therapeutics, Inc.

NasdaqGS:AARD Stock Report

Market Cap: US$124.4m

Aardvark Therapeutics Management

Management criteria checks 0/4

Aardvark Therapeutics' CEO is Tien-Li Lee, appointed in Mar 2017, has a tenure of 9.33 years. total yearly compensation is $6.07M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 7.11% of the company’s shares, worth $8.84M. The average tenure of the management team and the board of directors is 1.2 years and 1.9 years respectively.

Key information

Tien-Li Lee

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage10.40%
CEO tenure9.3yrs
CEO ownership7.1%
Management average tenure1.2yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

Seeking Alpha • May 18

Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward

Summary Aardvark Therapeutics, Inc. faces a pivotal regulatory setback as the FDA placed a clinical hold on ARD-101 due to unexpected cardiac signals. AARD now trades as a cash-backed option, with the stock reflecting little value beyond its $91M cash position and a 1.15x price-to-book ratio. Unblinding pivotal trial data could provide rapid safety clarity, but risks trial integrity and likely necessitates an additional confirmatory Phase 3 study. I maintain a neutral/hold stance on AARD until there is clearer FDA guidance, as regulatory resolution is the critical near-term catalyst. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Tien-Li Lee's remuneration changed compared to Aardvark Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$70m

Dec 31 2025US$6mUS$631k

-US$58m

Sep 30 2025n/an/a

-US$49m

Jun 30 2025n/an/a

-US$37m

Mar 31 2025n/an/a

-US$28m

Dec 31 2024US$906kUS$423k

-US$21m

Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$12m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$371kUS$370k

-US$7m

Compensation vs Market: Tien-Li's total compensation ($USD6.07M) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Tien-Li's compensation has increased whilst the company is unprofitable.

CEO

Tien-Li Lee (51 yo)

9.3yrs
Tenure
US$6,066,684
Compensation

Dr. Tien-Li Lee, M.D., has been the Founder of Aardvark Therapeutics, Inc. and serves as its Chief Executive Officer since March 2017 and serves as its Secretary and Director. He served as the Chief Strate...

Leadership Team

NamePositionTenureCompensationOwnership
Tien-Li Lee
CEO, Secretary & Director9.3yrsUS$6.07m7.11%
$ 8.8m
Nelson Sun
CFO & COO7.1yrsUS$2.55m2.12%
$ 2.6m
Manasi Jaiman
Chief Medical Officer1.8yrsUS$1.87m0%
$ 0
Timothy Kieffer
Chief Scientific Officer1.2yrsno datano data
Christian Zapf
General Counsel1.2yrsno datano data
Dvorit Samid
Executive Vice President of Medical Affairsno datano datano data
Zhenhuan Zheng
Chief Research Officer4.9yrsno datano data
Ron Lewis
VP & Head of CMC1.2yrsno datano data
Justin Stege
VP and Head of Project Management & Strategy1.2yrsno datano data
Danny Villeneuve
Chief Commercial Officer1.2yrsno datano data
Derrick Li
Chief Business Officerless than a yearno datano data
Bryan Jones
Chief Executive Officer of Ardialess than a yearUS$609.69k0%
$ 0
1.2yrs
Average Tenure
51yo
Average Age

Experienced Management: AARD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Tien-Li Lee
CEO, Secretary & Directorno dataUS$6.07m7.11%
$ 8.8m
Roy Baynes
Independent Director1.6yrsUS$325.94kno data
Chien-Chuen Chi
Lead Independent Director7.2yrsUS$608.87kno data
Victor Tong
Independent Director2.2yrsUS$588.87kno data
Susan Graf
Independent Director1.7yrsUS$339.13k0%
$ 0
1.9yrs
Average Tenure
55.5yo
Average Age

Experienced Board: AARD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 22:57
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aardvark Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
William WoodB. Riley Securities, Inc.
Suranjit MukherjeeBTIG